PPIDT00019
Drug Information
| Name | Pegfilgrastim |
|---|---|
| Sequence | MTPLGPASSLPQSFLLKCLEQVRKIQGDGAALQEKLCATYKLCHPEELVLLGHSLGIPWAPLSSCPSQALQLAGCLSQLHSGLFLYQGLLQALEGISPELGPTLDTLQLDVADFATTIWQQMEELGMAPALQPTQGAMPAFASAFQRRAGGVLVASHLQSFLEVSYRVLRHLAQP |
| DrugBank_ID | DB00019 |
| Type | biotech |
| Indication | Pegfilgrastim is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.[L44221] It is also indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome).[L44221] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Solution | — |
|
| Solution | Subcutaneous |
6 mg / 0.6 mL
|
| Injection | Subcutaneous |
6 mg/0.6mL
|
| Injection; kit | Subcutaneous |
6 mg/0.6mL
|
| Solution | Parenteral; Subcutaneous |
6 MG
|
| Solution | Subcutaneous |
10 mg / mL
|
| Solution | Subcutaneous |
6.000 mg
|
| Solution | Subcutaneous |
600000 mg
|
| Injection, solution | Subcutaneous |
6 mg
|
| Solution | Subcutaneous |
1000000 mg
|
| Solution | — |
5 mg/1ml
|
| Injection, solution | Subcutaneous |
|
| Injection, solution | Parenteral; Subcutaneous |
6 MG
|
| Injection, solution | Subcutaneous |
6 mg/0.6mL
|
| Injection, solution | — |
6 mg/0.6ml
|